| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
O-desmethyl Mebeverine acid targets muscarinic acetylcholine receptors (particularly M2 and M3 subtypes) on smooth muscle cells of the gastrointestinal tract, although with lower affinity than mebeverine. It also exhibits calcium channel blocking activity and direct smooth muscle relaxant effects, leading to reduced colonic motility and relief of abdominal pain and spasms.
|
|---|---|
| ln Vitro |
In vitro, O-desmethyl Mebeverine acid relaxes pre-contracted isolated intestinal smooth muscle strips from guinea pigs or rats at concentrations of 1-100 uM. It inhibits carbachol-induced contractions with an IC50 of approximately 5-15 uM, which is about 3-5 times less potent than mebeverine. It shows selectivity for intestinal over vascular smooth muscle. No significant cellular toxicity is observed at therapeutic concentrations.
|
| ln Vivo |
No specific in vivo activity data is available for this metabolite alone, as mebeverine is rapidly metabolized and the metabolite contributes to the overall therapeutic effect. In animal models of colonic hypermotility (e.g., stress-induced defecation in rats), mebeverine and its metabolites, including O-desmethyl mebeverine acid, reduce fecal pellet output at oral doses of 10-50 mg/kg.
|
| Enzyme Assay |
For receptor binding assays: Prepare membrane fractions from rat ileum smooth muscle cells. Incubate membranes with 3H-N-methylscopolamine (a muscarinic antagonist, 0.5-2 nM) and varying concentrations of O-desmethyl mebeverine acid (1 nM to 100 uM) in binding buffer (50 mM Tris-HCl, pH 7.4, 10 mM MgCl2) for 60 min at 25degC. Filter through glass fiber filters, wash, and count radioactivity. Calculate Ki values by competitive binding analysis. For functional assays, measure inhibition of carbachol-induced contraction in isolated ileal strips using organ baths.
|
| Cell Assay |
For smooth muscle contraction assays: Isolate longitudinal smooth muscle strips from guinea pig ileum (1 cm length). Mount in organ baths containing oxygenated Krebs-Henseleit buffer at 37degC. Apply 1 g tension and equilibrate for 45 min. Induce contraction with carbachol (1 uM). After stable contraction, add O-desmethyl mebeverine acid cumulatively (0.1-100 uM) and record relaxation. Calculate IC50 for inhibition of contraction. For cytotoxicity, culture human intestinal smooth muscle cells and treat with compound (1-200 uM, 24-48 h); assay viability by MTT.
|
| Animal Protocol |
For in vivo colonic motility studies in rats: Fast male Sprague-Dawley rats overnight. Administer O-desmethyl mebeverine acid (10, 30, or 100 mg/kg) orally in 0.5% carboxymethylcellulose. After 1 hour, induce colonic hypermotility by restraint stress (30 min) or by intracolonic administration of acetic acid (0.5 mL of 5% solution). Count fecal pellets expelled over 2 hours. Alternatively, measure intraluminal colonic pressure using an implanted telemetry probe. Compare to vehicle control and positive control (mebeverine).
|
| ADME/Pharmacokinetics |
After oral administration of mebeverine, O-desmethyl mebeverine acid is the major circulating metabolite. It has a plasma half-life of approximately 2-4 hours in humans. The metabolite is highly protein-bound (>90%). It is eliminated primarily via urine (as glucuronide conjugates) and to a lesser extent in feces. Peak plasma concentrations occur around 2-3 hours post-dose. No significant accumulation upon repeated dosing.
|
| Toxicity/Toxicokinetics |
O-desmethyl mebeverine acid is considered to have low toxicity, consistent with the safety profile of mebeverine. In preclinical studies, mebeverine and its metabolites have a high safety margin (LD50 >1000 mg/kg in rodents). The metabolite is not genotoxic in Ames tests. Common adverse effects of mebeverine (rare) include mild nausea, dizziness, and allergic reactions, which are unlikely to be attributed to this metabolite alone. No specific toxicity studies have been published for the isolated metabolite.
|
| Additional Infomation |
O-desmethyl mebeverine acid is a research-grade metabolite standard used for pharmacokinetic studies, bioanalysis, and quality control of mebeverine formulations. It is not a drug substance itself and is not intended for therapeutic use. The compound should be stored at -20degC, protected from light and moisture. It is soluble in DMSO and methanol, poorly soluble in water. No clinical trials are conducted with this metabolite alone.
|
| Molecular Formula |
C₁₅H₂₃NO₃
|
|---|---|
| Molecular Weight |
265.35
|
| Exact Mass |
265.168
|
| CAS # |
586357-02-0
|
| Related CAS # |
O-Desmethyl Mebeverine acid-d5;1329488-46-1;O-desmethyl Mebeverine acid-d5 hydrochloride;O-Desmethyl Mebeverine acid-d6;1630732-39-6;Mebeverine-d6 hydrochloride;1329647-20-2
|
| PubChem CID |
45038887
|
| Appearance |
White to light yellow ointment
|
| LogP |
2.509
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
19
|
| Complexity |
262
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(O)CCCN(CC)C(C)CC1=CC=C(O)C=C1
|
| InChi Key |
DJTCBAFIXOMULT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H23NO3/c1-3-16(10-4-5-15(18)19)12(2)11-13-6-8-14(17)9-7-13/h6-9,12,17H,3-5,10-11H2,1-2H3,(H,18,19)
|
| Chemical Name |
4-[ethyl-[1-(4-hydroxyphenyl)propan-2-yl]amino]butanoic acid
|
| Synonyms |
Odesmethyl Mebeverine acid; O desmethyl Mebeverine acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7686 mL | 18.8430 mL | 37.6861 mL | |
| 5 mM | 0.7537 mL | 3.7686 mL | 7.5372 mL | |
| 10 mM | 0.3769 mL | 1.8843 mL | 3.7686 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
